Stock Taper
EARNINGS CALL ARCHIVE 4 CALLS ON FILE
RIGL — Rigel Pharmaceuticals, Inc.
NASDAQ
FULL STOCK PAGE →

Q3 2025 Earnings Call Summary

NOV 4, 2025
REVENUE
$69.5M -31.7%
NET MARGIN
40.2% -18.5 PTS
EPS
$1.55 -53.5%
FREE CASH FLOW
$24.0M -21.3%

No summary has been written for this call yet.